European Pharmaceutical Pricing and Reimbursement Conference 2014

Market access remains one of the most significant current and future challenges for the industry. Spiralling drug development costs exert pressure to ensure successful and effective planning of your access strategies. With up to $5 billion in R&D costs for every successful drug launched, winning strategies are critical . Understanding the strengths and shortcomings in your people, processes and evidence are going to be the keys to your success. Planning around these key factors will enable increased market share for your organisation.

This year's conference will be held on 13-14 October. Now in its 20th year, this event has been one of the oldest market leaders in the pharmaceutical industries calendar for some time. Our expert speaking faculty; made up from key industry personnel from big pharma, biotech and academia will thoroughly explain and offer advice on P&R and market access. The 2014 agenda will focus on case studies as applied to different countries and environments in terms of market access.

Benefits of Attending:

Evaluate challenges within price discrimination

Implications of AMNOG featuring IGES institut, EUCOPE and Ministry of Health, Germany

Case study from Ipsen on latest developments in pharmaceutical pricing

Analyse the impact of Value Based Assessment on SMEs

Gain further insight on how to engage effectively with payers

Key presentation on the IMI GetReal Consortium

Ample networking opportunities , including a drinks reception on the close of Day One sponsored by Quintiles

Key Speakers:

Leyla Hannbeck, Head of Pharmacy Services, National Pharmacy Association

Silke Baumann, Head of Unit, Pricing, Assessment and Reimbursement of New Medicines, Ministry of Health, Germany

Rodolphe Perard, Associate Director, Market Access, Gilead

Francois Bernard, Head of Market Access, Mundipharma<br